News | October 08, 2009

Survey Shows Increased Cardiac Issues Due to Economic Downturn

October 8, 2009 – In a recent survey of more than 2,000 U.S. physicians conducted by Epocrates Inc., cardiologists and other specialists shared their perspective on the latest patient visit trends and mobile technology use. With patient visits highly affected by the economy, and the use of technology growing among cardiologists, the company said.

The survey found one in three cardiologists have seen more stress-related cases due to the economy. Nearly 70 percent of the physicians responding to the survey said they have seen an increase in cardiac issues related to stress due to the economic downturn. Due to the economic crisis, more than 85 percent of cardiologists have seen a rise in patients asking for lower cost prescriptions, and more than 65 percent of cardiologists have changed prescriptions based on electronic formulary information.

Nearly all specialists surveyed saw about 30 percent fewer patients in the first half of 2009, and attribute it to the economic downturn. Gastroenterologists and OBGYN physicians report the most decrease.
The survey also found cardiologists and gastroenterologists are the most satisfied with their career choice, but primary care and OBGYN physicians are least satisfied.

For more information: www.epocrates.com

Related Content

Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Overlay Init